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Backgrounds: Type I diabetes mellitus (T1DM), an autoimmune disease, is associated with insulin deficiency due to the death 
of -cells. Bone marrow-derived mesenchymal stem cells (BM-MSCs) are capable of tissue repair and thus are a promising source 
of -cell surrogates. 
Methods: In this study, the therapeutic potential of BM-MSCs as -cell replacements was analyzed both in vitro and in vivo. First,
we used retinoic acid (RA) to induce rat BM-MSCs to differentiate into cells of endodermal/pancreatic lineage. Then, differentiated 
rat BM-MSCs were syngeneically injected under the renal capsule of rats. 
Results: Analysis of gene expression revealed that rat BM-MSCs showed signs of early pancreatic development, and differentiated 
cells were qualitatively and quantitatively confirmed to produce insulin in vitro. In vivo study was performed for short-term (3 
weeks) and long-term (8 weeks) period of time. Rats that were injected with differentiated MSCs exhibited a reduction in blood 
glucose levels throughout 8 weeks, and grafted cells survived in vivo for at least 3 weeks. 
Conclusions: These findings show that RA can induce differentiation of MSCs into the -cell lineage and demonstrate the potential 
of BM-MSCs to serve as therapeutic tools for T1DM.
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Type 1 diabetes mellitus (T1DM), an autoimmune disease 
associated with certain genetic human leukocyte antigen 
configurations, results in the death of pancreatic -cells due 
to continued autoimmune activity, thereby leading to insulin 
deficiency(1). During embryonic development, the pancreas 
originates from the foregut endoderm as ventral and dorsal 
buds(2). Pancreatic progenitor cells within the foregut epi-
thelium are marked by the expression of pancre-
atic-duodenal homeobox 1 (PDX-1), which can be activated 
by forkhead box A2 (FoxA2) and is required for pancreatic 
bud growth(3). PDX-1 expression is down-regulated in aci-
nar and ductal cells, maintained in differentiated endocrine 
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cells, and up-regulated in -cells(4). Also, Huang et al.(5) 
found that a pro-endocrine transcription factor, neurogenin 
3 (Ngn3), induces expression of essential -cell transcription 
factors, such as paired box gene 4 (Pax4), during pancreatic 
development.
Adult stem cells are widely used in medical research due 
to their unique properties of self-renewal and ability to dif-
ferentiate into multiple lineages(6). Two popular types of 
stem cell populations are contained in bone marrow (BM): 
hematopoietic stem cells and mesenchymal stem cells (MSCs). 
MSCs are favored for cell-based therapies because of their 
multipotency and immune-modulatory properties, with sev-
eral groups reporting the ability of MSCs to minimize the 
risk of graft-versus-host disease after allogeneic trans-
plantation in patients(7-11). MSCs can potentially be in-
duced to differentiate into -cell-like, insulin-producing cells 
via exposure to specific differentiation factors or genetic 
modification(12). Oh et al.(13) found that introducing 
MSCs into diabetic mice via subcapsular renal transplan-
tation lowered blood glucose levels, demonstrating that BM- 
derived cells are capable of differentiating into insulin-pro-
ducing cells and suggesting their potential application for 
T1DM treatment. 
The expansion of -cells from a progenitor/stem cell source 
is a practical solution to the shortage of donor islets, as sev-
eral research groups have shown that multipotent MSCs are 
capable of giving rise to functional endoderm(13-16), and 
numerous studies show that stem cells of various origins can 
differentiate into islet-like cells(17,18). Furthermore, sev-
eral studies have demonstrated that progenitor/stem cells, 
including BM-derived cells, can differentiate into insulin- 
secreting cells in vitro, and transplantation of these differ-
entiated cells into diabetic mice reduces hyperglycemia 
(13,19-21).
All-trans retinoic acid (RA) is a signaling molecule in-
volved in the development of neuroectoderm and mesoderm 
in vertebrates. RA also regulates early pancreatic bud for-
mation during embryogenesis and enhances insulin ex-
pression in pancreatic -cells(22), and RA signaling is in-
volved in the emergence of Pdx1-expressing progenitor 
cells(23). Cavallari et al.(24) demonstrated that RA, cou-
pled with hyaluronic and butyric acids, can improve islet re-
vascularization when islets are co-transplanted with stem 
cells into diabetic rats. Here, we examined the potential of 
RA to induce differentiation of rat BM-derived MSCs into 
the -cell lineage in vitro without using growth factors. 
Furthermore, we investigated the potential in vivo ther-
apeutic use of differentiated, insulin-secreting MSCs for 
T1DM.
MATERIALS AND METHODS
1. Cell isolation and expansion 
Rat BM-derived MSCs (rBM-MSCs) were isolated from 
male 10-week-old Sprague Dawley (SD) rats (Orient, 
Seongnam, Korea). After sacrifice, the femora and tibiae 
were removed. Both ends of the bones were cut off, and 
BM aspirate was obtained by irrigation of phosphate buf-
fered saline (PBS) through the bone using a syringe. 
Aspirate was suspended in PBS, filtered through a cell 
strainer with 100-m pore size, and centrifuged at 800 ×g 
for 10 minutes and centrifuged at 800 ×g for 10 minutes. 
Supernatant was removed, and the remaining pellet was 
washed by re-suspending in PBS and centrifuging at 800 
×g for 5 minutes. After removal of supernatant, the pellet 
was re-suspended in low glucose Dulbecco’s Modified 
Eagle’s Medium (DMEM-lg, Life Technologies, Carlsbad, 
CA, USA) supplemented with 10% (v/v) heat-inactivated 
fetal bovine serum (FBS; Life Technologies), 100 U/mL 
penicillin, 100 g/mL streptomycin, and 25 g/mL am-
phortericin B (Antibiotic-Antimycotic, Life Technologies). 
Re-suspended cells were plated onto a 60-mm dish and cul-
tivated at 37oC in air containing 5% CO2. The next day, the 
medium was removed, and cells were washed with PBS six 
times to completely remove debris. Attached cells were ex-
panded, and the medium was changed every 3∼4 days. 
Cells at passage 3 were used in the experiments. 
2. Induction of pancreatic differentiation
rBM-MSCs were initially plated at a concentration of 
2,000∼2,500 cells/cm2. The next day, serum-free medium 
was applied for 48 hours prior to induction of differen-
tiation. The “base” differentiation medium consisted of 
DMEM-lg supplemented with FBS, antibiotics, 10 mM nic-
otinamide (Sigma-Aldrich, St. Louis, MO, USA), and 2 mM 
L-glutamine (Sigma-Aldrich). Cells were cultivated with 
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Table 1. Primers for rat bone marrow-derived mesenchymal stem cells





FoxA2 Sense: 5’-AAG GGA AAT GAC AGG CTG AGT GGA-3’ NM_012743.1 581 63 30
Antisense: 5’-TGT GGA ACT CTG GCA TTC TAG CCA-3’
PDX-1 Sense: 5’-TGC CAC CAT GAA TAG TGA GGA GCA-3’ NM_022852.3 394 63 30
Antisense: 5’-CGC GTG AGC TTT GGT GGA TTT CAT-3’
Ngn3 Sense: 5’-TTA CAA AGA TCG AGA CCC TGC GCT-3’ NM_021700.1 670 63 30
Antisense: 5’-AAG AGC CAG TGA GGT AAG ACG CAA-3’
Pax4 Sense: 5’-AGC TGA GGC ACT GGA GAA AGA GTT-3’ NM_031799.1 305 63 30
Antisense: 5’-AGC ACA GCT GAC AGA AGG AAG GAT-3’
C-peptide Sense: 5’-TGT CAA ACA GCA CCT TTG TGG TCC-3’ NM_019129.3 500 63 30
Antisense: 5’-AGT GGT GGA CTC AGT TGC AGT AGT-3’
Abbreviations: FoxA2, forkhead box A2; PDX-1, pancreatic-duodenal homeobox 1; Ngn3, neurogenin 3; Pax4, paired box gene 4; GAPDH,
glyceraldehyde 3-phosphate dehydrogenase.
this base medium for 4 days, and then 10 M RA (Sigma- 
Aldrich) dissolved in dimethyl sulfoxide (DMSO; Sigma- 
Aldrich) was added of the medium (1% of total volume) 
for 3 days. This 4/3 day cycle was repeated weekly. Cell 
morphology was monitored using an Olympus IX71inverted 
microscope (Olympus Optical Co., Tokyo, Japan).
3. Total RNA isolation and reverse-transcriptase 
polymerase chain reaction 
The RNeasy Kit (Qiagen, Venlo, Netherlands) was used 
to extract total RNA following the manufacturer’s 
instructions. One microgram isolated total RNA was treated 
with 0.5 g OligodT primer 12∼18 mer (Life Technolo-
gies) and incubated at 70oC for 5 minutes and then 4oC for 
5 minutes. Four microliters 5×reaction buffer, 2.4 L 
MgCl2, 1 L deoxyribonucleotide triphosphates, and 1 L 
ImProm-II reverse transcriptase (Promega, Fitchburg, WI, 
USA) were added to the mixture. The mixture was then in-
cubated at 25oC for 5 minutes, 42oC for 1 hour, and 70oC 
for 5 minutes to synthesize cDNA. The product was main-
tained at 4oC. 
Synthesized cDNA product was quantified and trans-
ferred into AccuPower polymerase chain reaction (PCR) 
premix (Bioneer, Daejeon, Korea) with primers. PCR was 
performed in a DNA thermal cycler 2720 (Life Technolo-
gies). An initial denaturation condition of 94oC for 5 mi-
nutes was applied to all primer sets, followed by 35 cycles 
of 94oC for 30 seconds, specific annealing temperatures for 
30 seconds, and 72oC for 30 seconds or 1 minute for primers 
with product sizes of less or greater than 500 bp, respecti-
vely (Table 1). A final extension step of 72oC for 5 minutes 
was completed after the last cycle. PCR products were load-
ed into wells in 1.8% agarose gel for electrophoresis. 　
4. Fluorescence-activated cell sorting analysis 
MSCs were harvested after detachment with 0.25% tryp-
sin-ethylenediaminetetraacetic acid (Life Technologies). Cells 
were washed with 0.2% (w/v) bovine serum albumin (BSA; 
Sigma-Aldrich) in PBS and collected by centrifugation at 
2,000 rpm for 5 minutes. Fluorescein isothiocyanate-con-
jugated CD29, CD45, CD90 (BD Biosciences, Franklin Lakes, 
NJ, USA), and CD34 (Santa Cruz Biotechnology, Dallas, 
TX, USA) antibodies were used for rBM-MSCs. Analysis 
was performed for at least 10,000 cells/sample using fluo-
rescence-activated cell sorting Calibur and Cell Quest soft-
ware (BD Biosicences). 
5. Immunocytochemistry 
rBM-MSCs at week 3 were fixed in 10% formaldehyde 
solution for 30 minutes at room temperature after washing 
with PBS. Fixed cells were washed three times with PBS, 
permeabilized by incubation in 100% ice-cold methanol for 
5 minutes, and washed again washed three times with PBS. 
Non-specific binding was blocked with 5% (w/v) BSA sol-
ution in PBS by incubation at room temperature for 45 
minutes. Cells were then incubated in insulin (H-86) pri-
  121
Jae Hyung Kim, et al: Retinoic Acid-induced Stem Cell Differentiation
Fig. 1. Fluorescence-activated cell sorting analysis for characterization of rat mesenchymal stem cells (MSCs) at passage 3. Abbreviation: 
IgG, immunoglobulin G. 
mary antibody (Santa Cruz Biotechnology) diluted 1:200 in 
1% BSA solution overnight on a shaking plate in a cold 
room. Cells were washed three times with PBS for 5 minutes 
at room temperature and then incubated with CruzFluo 
(CFL)-conjugated (maximum excitation wavelength of 488 
nm) goat anti-rabbit immunoglobulin G (IgG; Santa Cruz 
Biotechnology) secondary antibody diluted 1:200 in 1% BSA 
solution for 1 hour at room temperature in a container cov-
ered with foil. Cells were washed three times with PBS for 
10 minutes. Prior to observation, cell nuclei were stained 
with 4’,6-diamidino-2-phenyindole (Sigma-Aldrich). Immuno- 
stained cells were observed using an Olympus IX71fluore-
scence light microscope, and images were obtained and ana-
lyzed using a CCD DP71 digital camera and DP Controller 
software (Olympus Optical Co.). 
6. Enzyme-linked immunosorbent assay
Culture media from differentiated hBM- and rBM-MSCs 
at week 3 was collected and stored at −20oC. Enzyme- 
linked immunosorbent assay (ELISA) analysis was per-
formed using the Rat Insulin ELISA Kit (Shibayagi, Shibu-
kawa, Japan) following the manufacturers’ instructions. 
Reactivity at 450 nm was measured using the Versa Max 
ELISA reader (Molecular Devices, Sunnyvale, CA, USA). 
Measured values were converted to insulin concentrations 
using references supplied by the manufacturers. 
7. Syngeneic graft of rBM-MSCs
Animal study was approved by Department of Laboratory 
Animal Resources, which is an Institutional Animal Care 
and Use Committee and a designated Association for Asse-
ssment and Accreditation of Laboratory Animal Care Inter-
national facility, Yonsei Biomedical Research Institute, 
Yonsei University College of Medicine, and the entire pro-
cedure was performed under control. Meloxicam (1 mg/kg 
body weight) was daily applied to ameliorate suffering, and 
gentamicin was used as antibiotics. Animals were sacrificed 
by CO2 gas. 
Male SD rats (250∼300 g, 8∼9 weeks old) were housed 
at the Department of Laboratory Animal Medicine at 
Yonsei University College of Medicine, under a 12-hour- 
day/night cycle with access to water and standard rat chow. 
Experimental diabetes was induced by intraperitoneal in-
jection of 80 mg/kg streptozotocin (STZ; Sigma-Aldrich) 
dissolved in 100 mmol/L citrate buffer (pH 4.5) at a volume 
of 1 L/kg body weight. Glucose levels were checked every 
three days with an Optium blood glucose monitoring device 
(Abbott Laboratories, Abbott Park, IL, USA) using blood 
obtained by cutting the tip of the tail. Blood glucose levels 
above 500 mg/dL were recorded as 500.
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Fig. 2. Morphological changes of differentiated rat bone marrow-derived mesenchymal stem cells. (A, B) Week 1. (C, D) Week 2. (E, F)
Week 3 (A, C, E: ×40; B, D, F: ×100).
Diabetic rats (glucose level ＞450 mg/dL) received syn-
geneic grafts of rBM-MSCs that had been cultured for 3 
weeks. Cells were labeled with the red fluorescent cytoplas-
mic stain PKH26 (Sigma-Aldrich), and 1×106 cells sus-
pended in 50 L medium were injected under the surface 
of the left kidney capsule using a 30-gauge needle. Rats in-
jected with medium (sham; n=4) or rBM-MSCs (n=9) were 
observed over a 3-week period, and rats injected with dif-
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Fig. 3. Reverse-transcriptase polymerase chain reaction of rat 
bone marrow-derived mesenchymal stem cells (rBM-MSCs). Lanes
1 to 3: differentiated rBM-MSCs from week 1 to 3. Abbreviations:
FoxA2, forkhead box A2; PDX-1, pancreatic-duodenal homeobox 
1; Ngn3, neurogenin 3; Pax4, paired box gene 4; GAPDH, glyce-
raldehyde 3-phosphate dehydrogenase.
ferentiated MSCs (n=8) were observed over an 8-week- 
period. Non-diabetic rats were observed as positive controls, 
and untreated STZ-induced rats were observed as negative 
controls. Glucose levels were checked every 3 days. Neph-
rectomy of the graft-bearing kidney was performed at the 
end of the observation period, and rats were monitored for 
an additional 6 days. 　
8. Immunohistochemistry 
Removed graft-bearing kidneys were frozen in plastic 
molds filled with Tissue-Tek OC compound at −70oC and 
cryosected at a thickness of 6 m. Slides were incubated in 
acetone for 10 minutes and then washed twice with distilled 
water on a shaking plate. ImmEdg Pen (Vector Laborato-
ries, Burlingame, CA, USA) was applied to slides around the 
tissue prior to antibody binding. Tissue was incubated with 
insulin antibody (H86) diluted 1:200 at 4oC overnight. 
Slides were washed three times in PBS on a shaking plate 
for 5 minutes. Tissue was then incubated with horseradish 
peroxidase-conjugated goat anti-rabbit IgG (Life Technolo-
gies) diluted 1:250 for 1 hour at room temperature. Slides 
were washed three times in PBS on a shaking plate for 5 
minutes. Streptavidin (Dako, Glostrup, Denmark) was di-
luted 1:200 and reacted with the tissue for 1 hour. Slides 
were washed twice in PBS on a shaking plate for 5 minutes. 
The 3,3’-diaminobenzidine substrate kit (Vector Laborato-
ries) was used to stain tissue sections following the manu-
facturer’s instructions. Slides were then washed with dis-
tilled water twice for 5 minutes on a shaker, and Accustain 
Harris Hematoxylin Solution was applied for 1 minute as 
a counterstain. Slides were washed with flowing water fol-
lowed by absolute alcohol and xylene and then cov-
er-slipped with Permount (Fisher Scientific, Hampton, NH, 
USA). Tissue was observed using a fluorescence light 
microscope. 
9. Statistical analysis 
Quantitative results are expressed as mean±standard 
deviation. Paired t-tests were used to compare groups using 
GraphPad Prism 6 for Windows (GraphPad Software, Inc., 
La Jolla, CA, USA). Statistical significance was set at P＜ 
0.05.
RESULTS 
1. Characterization of rBM-MSCs 
rBM-derived cells were predominately positive for CD29 
and CD90 (94.47% and 83.72%, respectively) (Fig. 1) but 
negative for CD34 and CD45 (both 0.02%). Prior to in-
duction of differentiation, cells were spindle-shaped with 
typical MSC-like morphology (Fig. 2). 
2. Morphology of differentiated rBM-MSCs 
After RA treatment, morphological changes of rBM- 
MSCs were monitored on a weekly basis. rBM-MSCs 
showed considerable alterations in their appearance across 
weeks (Fig. 2). Cells typically exhibited polygonal or round 
shapes with radial nuclei.
3. Reverse-transcriptase PCR of differentiated rBM- 
MSCs
Primers were selected from representative markers from 
each step of pancreatic differentiation of rBM-MSCs: FoxA2, 
PDX-1, Ngn3, Pax4, and C-peptide. Primers for rBM-MSCs 
corresponded to those for hBM-MSCs: FoxA2, PDX-1, 
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Fig. 4. Immunocytochemistry of differentiated rat bone marrow- 
derived mesenchymal stem cells at week 3. (A) Insulin (green). 
(B) 4’, 6-diamidino-2-phenyindole (DAPI, blue). (C) Light 
microscopic image. (D) Merged insulin and DAPI images. (E) 
Merged insulin, DAPI, and light microscopic images 
(magnification, ×100; scale bar=200 m).
Ngn3, Pax4, and C-peptide for rodents. The expression pat-
terns of differentiated rBM-MSCs had no expression of 
Pax4, minimal expression of FoxA2 and Ngn3, and up-regu-
lation of PDX-1 and C-peptide at week 3 (Fig. 3). 
4. Qualitative and quantitative analysis of insulin 
expression in hBM- and rBM-MSCs 
Differentiated rBM-MSCs were incubated with insulin 
primary antibody and labeled with green fluorescent 
CFL-488-conjugated secondary antibody. Insulin expression 
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Fig. 5. Insulin secretion from differentiated rat bone marrow- 
derived mesenchymal stem cells (MSCs) measured by enzyme- 
linked Immunosorbent Assay at week 3 (n=9). aP<0.05.
was clearly observed in differentiated cells (Fig. 4). 
ELISA revealed that differentiated rBM-MSCs showed a 
2.063-fold increase in insulin secretion, which was signifi-
cantly higher than that observed for MSCs cultivated in 
normal medium (P＜0.05; Fig. 5). 
5. Syngeneic graft of rBM-MSCs in vivo
Non-diabetic (＋control) and STZ-injected rats (sham) 
exhibited obvious differences in blood glucose levels, with 
non-diabetic rats maintaining normoglycemia but diabetic 
rats exhibiting hyperglycemia (Fig. 6A). Diabetic rats that 
received normal MSCs showed no reduction of hyper-
glycemia across the 3-week observation period, whereas dia-
betic rats that received differentiated MSCs showed a mod-
est decrease in blood glucose level (Fig. 7B). Linear re-
gression analysis revealed that differentiated MSCs reduced 
blood glucose levels more rapidly than normal MSCs (slope 
for the differentiated MSC-injected group=−1.728±0.7725 
vs. slope for the normal MSC-injected=−0.4935±0.5103) 
(Fig. 6D).
When we continued to observe differentiated MSC-in-
jected rats for an additional 5 weeks, we found that blood 
glucose levels remained below 400 mg/dL throughout the 
entire observation period (Fig. 6C). Furthermore, rats ex-
hibited a rise in blood glucose levels after nephrectomy of 
the grafted kidney.　
6. Histological observation of grafted rBM-MSCs
rBM-MSCs were labeled with red fluorescent PKH26 pri-
or to their injection. Three weeks after injection, we ob-
served labeled cells mostly along the membrane near the in-
jection site, with some cells partially migrating into the kid-
ney (Fig. 8). Insulin- and hematoxylin-stained images show 
that grafted cells successfully survived along the inner sur-
face of the tissue membrane (Fig. 7).
DISCUSSION
The generation of insulin-producing -cell surrogates 
from progenitor/stem cells in vitro has remarkable potential 
for a cell-based therapy for T1DM(13,17-21). However, the 
in vivo therapeutic success of mature -cell alternatives has 
yet to be demonstrated. BM-MSCs exhibit great capacities 
for differentiation and plasticity. Furthermore, they may be 
an ideal cell type for clinical use because they are more ac-
cessible for harvesting and adaptable to new environments 
compared with pancreatic islets(17). Over the past several 
years, we have genetically modified cells for T1DM treat-
ment and established insulin-producing cells in vitro(25,26). 
However, two major obstacles we encountered were low 
transfection efficiency and insufficient viability of cells to 
establish populations for in vivo trials. Therefore, in the 
present study, we focused on enhancing differentiation of 
cells in vitro while endeavoring to reduce the use of cyto-
toxic materials and/or growth factors. 
Three non-toxic reagents were used to induce -cell dif-
ferentiation of cultivated MSCs: nicotinamide, L-glutamine, 
and RA. Nicotinamide, also known as vitamin B3, has been 
reported to induce endocrine differentiation in pancreatic 
cells(27). Also, several groups report that L-glutamine in-
duces stem cells to become functional endoderm in hu-
mans(28). Moreover, several groups show that RA receptor 
signaling is required for the development of pancreatic pro-
genitor cells(29,30). As growth factors may induce uncon-
trollable cellular activities in vivo such as oncogenesis(31), 
we eliminated growth factors from the cultivation medium 
and attempted to use a limited number of reagents to ach-
ieve sufficient -cell differentiation. 
RA, in particular, is an essential substance for -cell dif-
ferentiation and is closely associated with expression of 
PDX-1(29,32). PDX-1, a marker of early pancreatic pro-
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Fig. 6. Blood glucose levels of rats observed for 3 (A, B) or 8 (C) weeks. (A) Positive control (n=4) and sham control (n=4). (B) Blood
glucose level of normal mesenchymal stem cell (MSC)-injected (n=9) and differentiated MSC-injected (n=8) rats. (C) Positive control 
(n=4) and differentiated MSC-injected (n=8) rats. (D) Linear regression of blood glucose levels from MSC-injected (n=9) and differentiated
MSC-injected (n=8) rats. Slope for MSC-injected group=−0.4935±0.5103; slope for differentiated MSC-injected group=−1.728±0.7725.
genitor cells and mature -cells, is a well-established sign of 
-cell differentiation(32-34), and overexpression of PDX-1 
alone may induce differentiation of MSCs into in-
sulin-producing cells that are responsive to glucose stim-
ulation(17). Consistent with these findings, our reverse- 
transcriptase PCR and ELISA results show that PDX-1 ex-
pressed with insulin secretion (Fig. 5) in rat (Fig. 3) MSCs 
in vitro. As Ostrom et al.(30) reports, RA is at least partly 
required for the development of dorsal pancreatic mesen-
chyme during early pancreas development. Our results show 
that MSCs from rats secreted insulin (Fig. 5) and express 
C-peptide (Fig. 3). Nevertheless, we conclude that these cells 
cannot be considered as -cells but only as candidates with 
potential. Limitations clearly remain, which we are seriously 
taking into account to resolve in the next study.
T1DM is primarily an autoimmune disease, and, as a con-
sequence, graft function progressively declines due to the 
loss of functional islets during the early post-transplantation 
period(35). Therefore, the present study focused on MSCs, 
which could play a major role in tissue regeneration through 
localized immune-suppressive effects. To increase the func-
tional activity of MSCs in vivo, we induced their differ-
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Fig. 7. 3,3’-Diaminobenzidine-stained tissue. (A) Cells located along the inner surface of the tissue membrane. (B) Cell that migrated a
short distance into the tissue (marked by yellow arrowhead) (magnification: ×100; scale bar=200 m).
Fig. 8. PKH26-labeled cells in kidney capsule (marked by yellow 
arrowheads). (A, B) Cell located along the inner surface of the 
tissue membrane. (C) Cells that migrated a short distance into the 
tissue (magnification: ×100; scale bar=200 m).
entiation by culturing MSCs in a customized differentiation 
medium for 3 weeks before their graft into the left kidney 
capsule of rats. Differentiated MSCs were modestly more 
effective than undifferentiated cells in reducing blood glu-
cose levels (Fig. 6), and differentiated MSCs successfully 
survived in the kidney for at least 3 weeks (Fig. 7, 8). 
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Furthermore, after nephrectomy of the grafted kidney, rats 
exhibited a return of high blood glucose levels. Although 
T1DM is an acute disease, we assume that grafted MSCs 
may enable chronic recovery, aiding in secretion of insulin. 
Several research groups report that RA can regulate the 
commitment of embryonic stem cells to establish pancreatic 
endoderm(29,30,36). However, detailed in vivo evidence of 
recovered function does not exist, and there has been no 
attempt to use MSCs, which entail fewer ethical concerns 
and are more clinically applicable. Thus, the results of the 
present study are compelling, as they clearly show a reduc-
tion in blood glucose levels and the survival of MSCs 3 
weeks after injection. We conclude that RA-induced -cell 
differentiation of BM-MSCs may have great therapeutic po-
tential for T1DM. 
One may argue that the sustained reduction of blood glu-
cose levels in the present study was still too high to be con-
sidered normoglycemia. However, we find this data to be 
meaningful because only a very low number of cells (1× 
106 cells per rat) were injected into rats. Increasing the 
number of injected cells could be explored in future studies 
as a way to improve the effectiveness of this potential ther-
apeutic tool. Furthermore, diabetic rats initially exhibited 
excessively high levels of blood glucose, (i.e., typically above 
500 mg/dL), meaning that the observed reduction in blood 
glucose levels could be considered evidence that the differ-
entiated cells aided in the recovery of insulin secretion. It 
is also noteworthy that blood glucose level appeared to be 
continuously regulated, without a single instance of a rapid 
return to hyperglycemia throughout both the short- and 
long-term observation periods. 
CONCLUSION
In summary, we showed that RA can induce the differ-
entiation of rBM-MSCs into the -cell lineage, resulting in 
cells that have the ability to secrete insulin. Furthermore, 
the success of grafted MSCs in a rat model of diabetes sug-
gests that MSCs can potentially serve as -cell surrogates 
within therapies for T1DM. 
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